A new urine test for lung cancer is in development and could potentially be introduced into the NHS within five years, according to experts. This innovative test targets “zombie cells” that indicate the presence of cancer well before symptoms manifest, offering a significant advancement in early detection efforts. Researchers from Cambridge University and Royal Papworth Hospital have conducted trials using human urine samples to address the pressing issue of lung cancer, which currently accounts for a high number of cancer-related deaths in the UK.
Lung cancer is responsible for approximately 33,000 deaths annually in the UK, underscoring the urgency for improved diagnostic methods. Most cases are detected in advanced stages, posing challenges for effective treatment.
Professor Ljiljana Fruk, a prominent figure from the University of Cambridge, expressed optimism about the potential impact of this simple urine test in the fight against lung cancer. The test relies on identifying senescent or “zombie cells” associated with cancer development, which have the ability to persist in tissue, evade immune responses, and release harmful substances that contribute to inflammation and cell damage.
Through extensive genetic analysis, scientists pinpointed a specific protein produced by these zombie cells. They have devised a sensor that, when introduced into the body, interacts with the protein to produce a detectable compound in urine, indicating the presence of these cells.
While the sensor has yet to undergo human testing, it shows promise for future clinical trials and eventual integration into healthcare facilities for early detection of lung cancer recurrence. Patrick Keely, a spokesperson for Cancer Research UK, which supported the research, praised the groundbreaking nature of this technology in advancing early cancer detection efforts.
Published in the journal Nature Ageing, researchers detailed the validation of the biomarker in human tissue using actual patient samples. The potential application of the urine sensor extends beyond lung cancer and may also prove effective in detecting other cancers or lung conditions like pulmonary fibrosis.
Furthermore, the research team is exploring adaptations of the probe for detecting various types of cancer, exemplifying the versatility and potential impact of this innovative approach in cancer diagnostics.
Professor Daniel Munoz-Espin, co-lead of the Cancer Research UK Cambridge Centre Thoracic Cancer Programme, emphasized the critical role of senescent cells in cancer progression and treatment resistance. The urine nano sensor holds promise for detecting therapy resistance and early lung cancer development in primary care settings, offering a new frontier in cancer management.
The advancements in early cancer detection underscore the ongoing progress in medical research, highlighting the transformative potential of cutting-edge technologies in combating life-threatening diseases.
